There are already two drugs on the market targeting KRAS mutations, for decades considered ... in the phase 1/2 LOXO-RAS-20001 study, which included 17 previously untreated patients.

Cancer patients invariably develop resistance to targeted drugs, so drugmakers develop strategies to combat it before ...

Cancer patients invariably develop resistance to targeted drugs, so drugmakers develop strategies to combat it before ...

So, I think that’s kind of how you look at it.” Gutekunst said the team doesn’t use RAS “at all.” Rather the team’s analytics staff has its own tool to “measure athletic traits and ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., April 24, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new and updated data from ...

During a live event, Xiuning Le, MD, PhD, discussed updated intracranial efficacy, overall survival, and safety of ...

A mutation is any detectable and heritable change in nucleotide sequence that causes a change in genotype and is transmitted to daughter cells and succeeding generations. Tools for diversifying ...

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...

Non-small-cell lung cancer (NSCLC) treatment has led to improved efficacy and compliance due to individual tailoring of the therapeutic options and the use of strategies based on both clinical ...

Targeted therapies directed against the ErbB receptor family pathway include antibodies, such as cetuximab ... patients with EGFR mutations, and this finding led to the regulatory approval ...